Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-infusion of haploidentical stem cells and single-unit cord blood for high-risk allogeneic HSCT
NL-OMON34968Phase 2Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2010
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of haploidentical hematopoietic stem cells and umbilical cord blood stem cells in hematopoietic malignancies, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and 4 more, sponsored by University Medical Center Utrecht. Primary endpoints: Transplant-related mortality and Acute graft-versus-host disease. Planned start Oct 2010; status: withdrawn.
02
Drugs
haploidentical hematopoietic stem cellsumbilical cord blood stem cells
03
Conditions
hematopoietic malignanciesacute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NL-OMON34968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34968.